- Home
- RMTI vs AKTX Comparison
RMTI vs AKTX Comparison
Compare RMTI & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- AKTX
- Stock Information
- Founded
- RMTI 1994
- AKTX N/A
- Country
- RMTI United States
- AKTX United States
- Employees
- RMTI N/A
- AKTX N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- RMTI Health Care
- AKTX Health Care
- Exchange
- RMTI Nasdaq
- AKTX Nasdaq
- Market Cap
- RMTI 32.5M
- AKTX 35.7M
- IPO Year
- RMTI 1998
- AKTX N/A
- Fundamental
- Price
- RMTI $0.93
- AKTX $1.03
- Analyst Decision
- RMTI Strong Buy
- AKTX Strong Buy
- Analyst Count
- RMTI 2
- AKTX 1
- Target Price
- RMTI $4.00
- AKTX $5.00
- AVG Volume (30 Days)
- RMTI 460.0K
- AKTX 23.5K
- Earning Date
- RMTI 08-14-2025
- AKTX 08-18-2025
- Dividend Yield
- RMTI N/A
- AKTX N/A
- EPS Growth
- RMTI N/A
- AKTX N/A
- EPS
- RMTI N/A
- AKTX N/A
- Revenue
- RMTI $97,727,000.00
- AKTX N/A
- Revenue This Year
- RMTI N/A
- AKTX N/A
- Revenue Next Year
- RMTI $11.16
- AKTX N/A
- P/E Ratio
- RMTI N/A
- AKTX N/A
- Revenue Growth
- RMTI 12.82
- AKTX N/A
- 52 Week Low
- RMTI $0.78
- AKTX $0.85
- 52 Week High
- RMTI $5.15
- AKTX $4.22
- Technical
- Relative Strength Index (RSI)
- RMTI 40.24
- AKTX 35.47
- Support Level
- RMTI $1.08
- AKTX $1.01
- Resistance Level
- RMTI $1.18
- AKTX $1.15
- Average True Range (ATR)
- RMTI 0.08
- AKTX 0.04
- MACD
- RMTI -0.02
- AKTX -0.01
- Stochastic Oscillator
- RMTI 6.01
- AKTX 14.29
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.